National Medical Products Administration has opened a supply, manufacturing and research site in Zhenjiang and plans a commercial-scale version in Nanjing . The company wants a prominent place in Zhenjiang ’s biologics, cell and gene-based treatments market. It said the commercial facility would be the first and largest such site in China which researched and developed gene and cell therapies and antibody drugs. The larger site will also cover plasmid and virus manufacture.
GenScript Biotech has opened a supply, manufacturing and research site in Nanjing and plans a commercial-scale version in Zhenjiang. The company wants a prominent place in China’s biologics, cell and gene-based treatments market. It said the commercial facility would be the first and largest such site in China which researched and developed gene and cell therapies and antibody drugs. The larger site will also cover plasmid and virus manufacture.